NCT03546387

Brief Summary

The purpose of this study is to see if there is a difference between the development of the brain (neurodevelopment) in children who have been treated for retinoblastoma with multiple anesthetic exposures, compared with brain development in children who have never had anesthesia.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
75

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2018

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 7, 2018

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

May 8, 2018

Completed
29 days until next milestone

First Posted

Study publicly available on registry

June 6, 2018

Completed
7.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 7, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 7, 2026

Completed
Last Updated

July 3, 2025

Status Verified

July 1, 2025

Enrollment Period

8 years

First QC Date

May 8, 2018

Last Update Submit

July 2, 2025

Conditions

Keywords

18-126Memorial Sloan Kettering Cancer Center

Outcome Measures

Primary Outcomes (1)

  • Comparing scores in neuropsychological testing results

    The primary outcome is based on the Wechsler Intelligence Scale for Children, 5th edition (WISC-V) measured at follow up. The 5 primary index scores on the WISC-V (Verbal Comprehension, Visual Spatial, Fluid Reasoning, Working Memory, and Processing Speed) are based on 10 subtests and represent intellectual functioning in different cognitive areas. Similar to the FSIQ, the primary index scores are on a standard score metric with a mean of 100 (SD=15). The WISC-V consists of 16 subtests; each subtest is based on a scaled score metric with a mean of 10 and standard deviation (SD) of 3. Performance on these domain-specific subtests will be summarized and analyzed similarly to the FSIQ.

    6 weeks

Interventions

the WISC-V assessment produces a Full Scale IQ (FSIQ) used for primary power consideration in this study. The FSIQ is the most comprehensive global ability score on the WISC-V, and it has been conventionally reported and interpreted as an estimation of overall intellectual ability

Used to assess verbal learning and memory in children and adolescents

Helps assess visual-motor skills in children and adults.

Measures dexterity

The Behavior Assessment System for Children/Parent Report is a questionnaire that assesses the social-emotional and behavioral functioning (e.g., anxiety, depression, attention, hyperactivity, adaptability, leadership, social skills, etc.) in children between the ages of 2 and 22 years, and is available in English and Spanish.

Eligibility Criteria

Age6 Years - 17 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

pediatric patients with retinoblastoma, between 6 and 16 years of age, at MSK.

You may qualify if:

  • Age ≥ 6 and \< 17 years old

You may not qualify if:

  • Diagnosis of any secondary disease associated with developmental delay
  • History of second cancer diagnosis
  • Legal Blindness
  • Past surgery of any type, with the exception of enucleation for retinoblastoma
  • Past exposure to anesthesia for surgical intervention
  • More than one anesthesia encounter for surgical intervention before diagnosis at MSK
  • Past External Beam Radiation for treatment of retinoblastoma
  • Past systemic chemotherapy
  • Non-native speaker of English; however, children whose parents speak only Spanish will be included, because the tests for parents are available in Spanish

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

RECRUITING

Related Links

MeSH Terms

Conditions

Retinoblastoma

Interventions

Wechsler ScalesMemory and Learning Tests

Condition Hierarchy (Ancestors)

Neoplasms, NeuroepithelialNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Glandular and EpithelialNeoplasms, Nerve TissueRetinal NeoplasmsEye NeoplasmsNeoplasms by SiteEye Diseases, HereditaryEye DiseasesRetinal Diseases

Intervention Hierarchy (Ancestors)

Intelligence TestsAptitude TestsPsychological TestsBehavioral Disciplines and ActivitiesNeuropsychological Tests

Study Officials

  • Vittoria Arslan Carlon, MD

    Memorial Sloan Kettering Cancer Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Vittoria Arslan Carlon, MD

CONTACT

David Abramson, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 8, 2018

First Posted

June 6, 2018

Study Start

May 7, 2018

Primary Completion

May 7, 2026

Study Completion

May 7, 2026

Last Updated

July 3, 2025

Record last verified: 2025-07

Locations